242 related articles for article (PubMed ID: 16767218)
1. Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity.
Chien J; Aletti G; Baldi A; Catalano V; Muretto P; Keeney GL; Kalli KR; Staub J; Ehrmann M; Cliby WA; Lee YK; Bible KC; Hartmann LC; Kaufmann SH; Shridhar V
J Clin Invest; 2006 Jul; 116(7):1994-2004. PubMed ID: 16767218
[TBL] [Abstract][Full Text] [Related]
2. HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation.
He X; Khurana A; Maguire JL; Chien J; Shridhar V
Int J Cancer; 2012 Mar; 130(5):1029-35. PubMed ID: 21387310
[TBL] [Abstract][Full Text] [Related]
3. HtrA1, a potential predictor of response to cisplatin-based combination chemotherapy in gastric cancer.
Catalano V; Mellone P; d'Avino A; Shridhar V; Staccioli MP; Graziano F; Giordani P; Rossi D; Baldelli AM; Alessandroni P; Santini D; Lorenzon L; Testa E; D'Emidio S; De Nictolis M; Muretto P; Fedeli SL; Baldi A
Histopathology; 2011 Apr; 58(5):669-78. PubMed ID: 21447133
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells.
He X; Ota T; Liu P; Su C; Chien J; Shridhar V
Cancer Res; 2010 Apr; 70(8):3109-18. PubMed ID: 20388781
[TBL] [Abstract][Full Text] [Related]
5. A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer.
Chien J; Staub J; Hu SI; Erickson-Johnson MR; Couch FJ; Smith DI; Crowl RM; Kaufmann SH; Shridhar V
Oncogene; 2004 Feb; 23(8):1636-44. PubMed ID: 14716297
[TBL] [Abstract][Full Text] [Related]
6. HtrA1 downregulation induces cisplatin resistance in lung adenocarcinoma by promoting cancer stem cell-like properties.
Xu Y; Jiang Z; Zhang Z; Sun N; Zhang M; Xie J; Li T; Hou Y; Wu D
J Cell Biochem; 2014 Jun; 115(6):1112-21. PubMed ID: 24356998
[TBL] [Abstract][Full Text] [Related]
7. Serine protease HtrA1 as an inhibitor on proliferation invasion and migration of gastric cancer.
Zhao Z; Li H; Wang C; Xu W; Sun J; Zhao W
Med Oncol; 2015 Apr; 32(4):112. PubMed ID: 25761858
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
9. HTRA1 promotes transdifferentiation of normal fibroblasts to cancer-associated fibroblasts through activation of the NF-κB/bFGF signaling pathway in gastric cancer.
Wu H; Ma S; Xiang M; Tong S
Biochem Biophys Res Commun; 2019 Jun; 514(3):933-939. PubMed ID: 31088682
[TBL] [Abstract][Full Text] [Related]
10. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer.
Lehner A; Magdolen V; Schuster T; Kotzsch M; Kiechle M; Meindl A; Sweep FC; Span PN; Gross E
PLoS One; 2013; 8(4):e60359. PubMed ID: 23580433
[TBL] [Abstract][Full Text] [Related]
12. Expression and functional significance of HtrA1 loss in endometrial cancer.
Mullany SA; Moslemi-Kebria M; Rattan R; Khurana A; Clayton A; Ota T; Mariani A; Podratz KC; Chien J; Shridhar V
Clin Cancer Res; 2011 Feb; 17(3):427-36. PubMed ID: 21098697
[TBL] [Abstract][Full Text] [Related]
13. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
16. Serine protease HtrA1 associates with microtubules and inhibits cell migration.
Chien J; Ota T; Aletti G; Shridhar R; Boccellino M; Quagliuolo L; Baldi A; Shridhar V
Mol Cell Biol; 2009 Aug; 29(15):4177-87. PubMed ID: 19470753
[TBL] [Abstract][Full Text] [Related]
17. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
Yang X; Fraser M; Moll UM; Basak A; Tsang BK
Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
[TBL] [Abstract][Full Text] [Related]
18. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
Mitsuuchi Y; Johnson SW; Selvakumaran M; Williams SJ; Hamilton TC; Testa JR
Cancer Res; 2000 Oct; 60(19):5390-4. PubMed ID: 11034077
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Taxane-Pretreated Metastatic Gastric Cancer with Excellent Response to Nab-Paclitaxel].
Kawabata R; Kimura Y; Kawase T; Yoshikawa M; Kameda C; Matsumura T; Koga C; Murakami M; Hirota M; Noura S; Ikenaga M; Shimizu J; Hasegawa J
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2088-90. PubMed ID: 26805273
[TBL] [Abstract][Full Text] [Related]
20. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
